Lv4
538 积分 2026-02-02 加入
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1天前
已完结
TNF-α: The shape of small molecules to come?
22天前
已完结
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
1个月前
已完结
[Guideline for HER2 testing in breast cancer (2024 version)]
1个月前
已完结
Glucose-dependent insulinotropic peptide and beyond: co-agonist innovations in the treatment of metabolic diseases
1个月前
已完结
皖公网安备34019202002308
